Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study

被引:2
|
作者
Praiss, Aaron M. [1 ]
Hirani, Rahim [1 ]
Zhou, Qin [1 ]
Iasonos, Alexia [1 ]
Sonoda, Yukio [1 ,2 ]
Abu-Rustum, Nadeem R. [1 ,2 ]
Leitao Jr, Mario M. [1 ]
Roche, Kara Long [1 ,2 ]
Broach, Vance [1 ,2 ]
Gardner, Ginger J. [1 ,2 ]
Chi, Dennis S. [1 ,2 ]
Zivanovic, Oliver [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY USA
[2] Weill Cornell Med Coll, Dept Obstet & Gynecol, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Intestinal resection; Postoperative morbidity; Anastomotic leak; Ovarian cancer; Primary cytoreductive surgery; Interval cytoreductive surgery; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; RECTOSIGMOID RESECTION; BOWEL RESECTIONS; FALLOPIAN-TUBE; RISK; ALGORITHM; SURVIVAL; DELAY;
D O I
10.1016/j.ygyno.2023.10.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestinal resection. Methods. A retrospective chart review was performed for patients with ovarian cancer who underwent PCS or ICS with at least one intestinal resection at our institution from 1/1/2015 to 12/31/2020. Progression-free survival (PFS) and overall survival (OS) were analyzed for the PCS and ICS cohorts separately. Short-term complications within 30 days of surgery (surgical secondary events [SSEs]) were graded by a validated institutional SSE system. Results. Among 437 patients who underwent intestinal resections during PCS (n = 289) or ICS (n = 148), 183 (42%) had one, 180 (41%) had two, and 74 (17%) had three intestinal resections. Six (1.4%) of 437 patients experienced an anastomotic leak postoperatively. There were no perioperative deaths. There was no difference in PFS and OS for patients who underwent PCS with any SSE vs. no SSE within 30 days of surgery (HR, 1.05; 95% CI: 0.76-1.47; p = 0.75 and HR, 0.79; 95% CI: 0.49-1.26; p = 0.32, respectively). There was no difference in PFS and OS for patients who underwent ICS with any SSE vs. no SSE within 30 days of surgery (HR, 1.43; 95% CI: 0.99-2.07; p = 0.055 and HR. 1.18; 95% CI: 0.72-1.93; p = 0.52, respectively. Conclusion. Short-term postoperative morbidity for patients who underwent intestinal surgery during primary surgical management for advanced ovarian cancer did not impact oncologic outcomes. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:169 / 179
页数:11
相关论文
共 50 条
  • [21] Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer
    Colombo, P. E.
    Labaki, M.
    Fabbro, M.
    Bertrand, M.
    Mourregot, A.
    Gutowski, M.
    Saint-Aubert, B.
    Quenet, F.
    Rouanet, P.
    Mollevi, C.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 223 - 230
  • [22] ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study
    Finch, Lindsey
    Broach, Vance
    Feinberg, Jacqueline
    Al-Niaimi, Ahmed
    Abu-Rustum, Nadeem R.
    Zhou, Qin
    Iasonos, Alexia
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2024, 189 : 75 - 79
  • [23] Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer
    Cascales Campos, P.
    Gil, Jose
    Parrilla, Pascual
    EJSO, 2014, 40 (08): : 970 - 975
  • [24] Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients
    Chen, Ming
    Chen, Zhanpeng
    Xu, Manman
    Liu, Duo
    Liu, Tianyu
    He, Mian
    Yao, Shuzhong
    JOURNAL OF CANCER, 2018, 9 (21): : 4087 - 4091
  • [25] Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
    Miralpeix, Ester
    Sole-Sedeno, Josep-Maria
    Rodriguez-Cosmen, Cristina
    Taus, Alvaro
    Muns, Maria-Dolors
    Fabrego, Berta
    Mancebo, Gemma
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [26] Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
    Ester Miralpeix
    Josep-Maria Sole-Sedeno
    Cristina Rodriguez-Cosmen
    Alvaro Taus
    Maria-Dolors Muns
    Berta Fabregó
    Gemma Mancebo
    World Journal of Surgical Oncology, 20
  • [27] Comparison of Morbidity and Survival Between Primary and Interval Cytoreductive Surgery in Patients After Modified Posterior Pelvic Exenteration for Advanced Ovarian Cancer
    Revaux, Aurelie
    Rouzier, Roman
    Ballester, Marcos
    Selle, Frederic
    Darai, Emile
    Chereau, Elisabeth
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (08) : 1349 - 1354
  • [28] Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
    Farolfi, Alberto
    Petracci, Elisabetta
    Gurioli, Giorgia
    Tedaldi, Gianluca
    Casanova, Claudia
    Arcangeli, Valentina
    Amadori, Andrea
    Rosati, Marta
    Stefanetti, Marco
    Burgio, Salvatore Luca
    Cursano, Maria Concetta
    Lolli, Cristian
    Zampiga, Valentina
    Cangini, Ilaria
    Schepisi, Giuseppe
    Giorgi, Ugo De
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer
    Tseng, Jill H.
    Cowan, Renee A.
    Afonso, Anoushka M.
    Zhou, Qin
    Iasonos, Alexia
    Ali, Narisha
    Thompson, Errika
    Sonoda, Yukio
    O'Cearbhaill, Roisin E.
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Roche, Kara Long
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 287 - 293
  • [30] Enhancing Prognosis in Advanced Ovarian Cancer: Primary Cytoreductive Surgery and Adjuvant Chemotherapy or Neoadjuvant Chemotherapy and Interval Cytoreduction-A Single-Center Retrospective Observational Study
    Gheorghe, Adelina Silvana
    Chirea, Irina Alexandra
    Margan, Madalin Marius
    Georgescu, Mihai-Teodor
    Komporaly, Isabela Anda
    Kajanto, Lidia Anca
    Iovanescu, Elena Adriana
    Georgescu, Bogdan
    Matei, Radu
    Zob, Daniela Luminia
    Mardare, Mara
    Ginghina, Octav
    Mihai, Mara Madalina
    Stanculeanu, Dana Lucia
    CANCERS, 2025, 17 (08)